Incyte Stock Investor Sentiment

INCY Stock  USD 51.74  0.09  0.17%   
Slightly above 61% of Incyte's investor base is looking to short. The analysis of the overall investor sentiment regarding Incyte suggests that many traders are alarmed. Incyte's investor sentiment overview provides quick insight into current market opportunities from investing in Incyte. The current market sentiment, together with Incyte's historical and current headlines, can help investors time the market. In addition, many technical investors use Incyte stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Panic Vs Confidence

39

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Incyte's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Incyte.
Incyte stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Incyte daily returns and investor perception about the current price of Incyte as well as its diversification or hedging effects on your existing portfolios.

Incyte Historical Sentiment

Although Incyte's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Incyte, such as negative comments on social media and news outlets, may cause fear in the market and push Incyte's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Incyte.
  

Incyte Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Incyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Incyte Historical Investor Sentiment

Investor biases related to Incyte's public news can be used to forecast risks associated with an investment in Incyte. The trend in average sentiment can be used to explain how an investor holding Incyte can time the market purely based on public headlines and social activities around Incyte. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Incyte's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Incyte and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Incyte news discussions. The higher the estimate score, the more favorable the investor's outlook on Incyte.

Incyte Maximum Pain Price across 2024-05-17 Option Contracts

Incyte's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Incyte close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Incyte's options.
a day ago at investing.com         
Incyte shares target cut to 84 by Oppenheimer on acquisition outlook
Investing News at Macroaxis
2 days ago at businesswire.com         
Samenvatting Incyte kondigt overname aan van Escient Pharmaceuticals en pijplijn van eersteklas oral...
businesswire News
2 days ago at businesswire.com         
Samenvatting Incyte kondigt overname aan van Escient Pharmaceuticals en pijplijn van eersteklas oral...
businesswire News
few days ago at news.google.com         
Federated Hermes Inc. Has 55.95 Million Holdings in Incyte Co. - MarketBeat
Google News at Macroaxis
six days ago at finance.yahoo.com         
Polycythemia Pipeline Insight 2024, Featuring Protagonist Therapeutics, Ionis Pharmaceuticals, Perse...
Yahoo News
over a week ago at finance.yahoo.com         
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
Yahoo News
over a week ago at finance.yahoo.com         
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
Yahoo News
over a week ago at finance.yahoo.com         
The past three years for Incyte investors has not been profitable
Yahoo News
over a week ago at finance.yahoo.com         
CertainBiotech Investors Get an Early Look at Results. Is That Fair?
Yahoo News
over a week ago at news.google.com         
Acquisition by Paul Clancy of 403 shares of Incyte at 56.97 subject to Rule 16b-3
Google News at Macroaxis
over a week ago at finance.yahoo.com         
Want Better Returns Dont Ignore These 2 Medical Stocks Set to Beat Earnings
Yahoo News
over a week ago at zacks.com         
Want Better Returns Dont Ignore These 2 Medical Stocks Set to Beat Earnings
zacks News
over a week ago at finance.yahoo.com         
Novartis to Undertake Job Cuts in Development Department
Yahoo News
over two weeks ago at investing.com         
Cathie Woods ARK ETFs adjust holdings, selling UiPath and Incyte stock
Investing News at Macroaxis
over two weeks ago at statnews.com         
Pfizers plot to win the RSV vaccine race
news
Far too much social signal, news, headlines, and media speculation about Incyte that are available to investors today. That information is available publicly through Incyte media outlets and privately through word of mouth or via Incyte internal channels. However, regardless of the origin, that massive amount of Incyte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Incyte news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Incyte relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Incyte's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Incyte alpha.

Incyte Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Earnings call MacroGenics reports 2023 financial results, clinical updates
03/08/2024
2
Resumen Incyte presenta nuevos datos de ltimo momento de un estudio fase 2 que evala povorcitinib en pacientes con prurigo nodular
03/11/2024
3
Why Is Incyte Up 1.8 percent Since Last Earnings Report
03/14/2024
4
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI310 in Combination with Sintilimab for MSI-HdMMR Colon Cancer Neoadjuvant Therapy
03/27/2024
5
Acquisition by Baker Bros. Advisors Lp of 543 shares of Incyte subject to Rule 16b-3
03/28/2024
6
Incyte, CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan, SEA
04/01/2024
7
Acquisition by Paul Clancy of 403 shares of Incyte at 56.97 subject to Rule 16b-3
04/02/2024
8
Pfizers plot to win the RSV vaccine race
04/09/2024
9
Want Better Returns Dont Ignore These 2 Medical Stocks Set to Beat Earnings
04/12/2024
10
The past three years for Incyte investors has not been profitable
04/15/2024
11
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer
04/16/2024
12
Samenvatting Incyte kondigt overname aan van Escient Pharmaceuticals en pijplijn van eersteklas orale MRGPR-antagonisten van het bedrijf
04/23/2024
When determining whether Incyte offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Incyte's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Incyte Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Incyte Stock:
Check out Incyte Hype Analysis, Incyte Correlation and Incyte Performance.
For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.
Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Incyte Stock analysis

When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.324
Earnings Share
2.65
Revenue Per Share
16.526
Quarterly Revenue Growth
0.093
Return On Assets
0.0646
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.